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Abstract
Background: A few studies have reported a positive association between phthalate exposure and pubertal timing,
but several conflicting reports exist. The main objective of the study was to determine whether phthalate exposure
was associated with central precocious puberty in girls.
Methods: This was a multicenter case-control study wherein 47 girls with central precocious puberty (CPP) and 47
controls (26 pre-pubertal girls and 21 pubertal girls) were enrolled. No obese girls were included. Five phthalate
metabolites (creatinine adjusted) and bisphenol A (BPA) were measured in the first spot urine samples of these 94
girls in the early morning.
Results: The median values of monobenzyl phthalate (MBzP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP),
mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), and mono-n-butyl
phthalate (MnBP) were 3.1, 29.3, 18.0, 15.4, and 25.2 μg/g creatinine in the CPP group, 4.3, 53.7, 35.7, 29.1, and
66.0 μg/g creatinine in the pre-pubertal control group, and 1.7, 28.7, 21.4, 12.1, and 33.3 μg/g creatinine in the
pubertal control group, respectively.
The urinary concentration of the five phthalates was significantly lower in the CPP group than in the pre-pubertal
control group (P < 0.001). Conversely, there was no significant difference in the urinary concentration of the five
phthalates between the CPP and pubertal control groups (P values: 0.077 for MBzP, 0.733 for MECPP, 0.762 for
MEHHP, 0.405 for MEOHP, and 0.981 for MnBP). In addition, the BPA level was not significantly different between
the CPP and pubertal control groups (BPA median values: 0.63 μg/g creatinine, the CPP group; 1.7 μg/g creatinine,
the pubertal control group; P value = 0.092).
Conclusions: Our study showed that there was no significant difference in the urinary phthalate levels between
the CPP and pubertal control groups. Moreover, phthalate metabolites were significantly lower in the CPP group
than in the pre-pubertal control group. Further investigation about endocrine disruptors and pubertal progression is
needed.
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Background
Precocious puberty is defined as the development of sec-
ondary sexual characteristics earlier than two standard devi-
ations of the mean value [1]. In recent times, children have
been attaining sexual maturity earlier than they would in
the past, and the incidence of precocious puberty is rising
worldwide [2]. Central precocious puberty (CPP) is the
result of precocious activation of the hypothalamic–pituit-
ary–gonadal axis, and the majority of CPP is idiopathic.
There has been considerable concern regarding the
presence of endocrine-disrupting chemicals (EDCs) in
the environment, which supposedly disturb the onset
and progression of pubertal development [3]. Phthalates
are synthetic chemicals that can provide flexibility and
durability to polyvinyl chloride products and are present
in a wide variety of consumer products, including food
packaging, plastic devices, toys, and cosmetics. The asso-
ciation between exposure to phthalates and pubertal
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onset has been explored, and the results were inconsist-
ent [4, 5]. Moreover, in experimental research, phtha-
lates exhibit both agonist and antagonist effects,
suggesting that pubertal development may be acceler-
ated or delayed depending the on timing, dose, and vari-
ous other factors in female rats [6].
Therefore, we assessed the urinary concentrations of
phthalate and bisphenol A (BPA) in girls with CPP and
control subjects to investigate the association between
exposure to phthalate and development of puberty in
Korean girls.
Methods
Study design and population
This case-control study was conducted at the Division of
Pediatric Endocrinology, Severance Hospital and Bundang
CHA Medical Center from 2015 to 2018. We enrolled 47
CPP patients and 47 healthy controls (26 pre-pubertal and
21 pubertal controls). All individuals were analyzed for
urinary phthalates and BPA. All participants were asked to
fill out questionnaire requesting the following data: per-
sonal information including where they live in a city or
rural area, usage habits, and dietary habits. The girls with
CPP and the controls lived in the same urban area, and
there were no specific eating habits or exposures to other
polluting materials including the use of plastic packaging.
Patients were identified as having idiopathic CPP if they
satisfied the following classical diagnostic criteria: (1) the
onset of breast development (Tanner stage B2 or above)
before 8 years of age, (2) a peak luteinizing hormone (LH)
level of 7 IU/L in the standard intravenous gonadotropin-
releasing hormone (GnRH) stimulation test, and (3) no
evidence of hypothalamic–pituitary organic lesions,
confirmed by magnetic resonance imaging. Subjects were
excluded if they had any additional condition that could
affect the onset of puberty, such as hypothyroidism or
congenital adrenal hyperplasia. Healthy controls were re-
cruited when children visited the clinic for growth assess-
ment. The inclusion criteria for pre-pubertal controls
were (1) 5 to 8 years of age (Tanner stage 1), and (2) bone
age (BA) not advanced 1 year more than the chronological
age (CA), and (3) no evidence of systemic illness or endo-
crinopathy. In addition, pubertal healthy controls (1) were
10 to 12 years old (Tanner stage 2 or above), (2) had BA
not advanced 1 year more than CA, and (3) showed no
evidence of systemic illness or endocrinopathy. Obese
children were also excluded. This study was approved by
the Institutional Review Board (IRB) of Severance Hospital
(No.2015–0917-007) and Bundang CHA Medical Center
(No.2017–09-029).
Clinical information and specimen collection
Anthropometric measurements were performed by well-
trained physicians, and height was measured using a
Harpenden stadiometer. BA was assessed using the
Greulich–Pyle method by the same observer [7]. Growth
parameters, such as height and body mass index (BMI),
were expressed as a standard deviation score (SDS),
which was calculated using the Korean children and ad-
olescents growth standard [8].
The first spot urine samples were collected in the early
morning of the appointment day for all participants.
Then, 10 mL of urine obtained from each subject was
stored in a polypropylene urine collection cup at − 20 °C
until assayed (polypropylene is not reported to contain
detectable levels of phthalate).
Analysis of urinary phthalates and BPA
Five phthalate metabolites (adjusted for creatinine), namely
monobenzyl phthalate (MBzP), mono-2-ethyl-5-carboxy-
pentyl phthalate (MECPP), mono-2-ethyl-5-hydroxyhexyl
phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate
(MEOHP), and mono-n-butyl phthalate (MnBP), and BPA
were measured. Briefly, after an aliquot (1.0mL) of urine
sample was enzymatically hydrolyzed and purified by solid-
phase extraction, the phthalate metabolites in the urine
were resolved by reversed-phase ultra-performance liquid
chromatography, detected by electrospray ionization tan-
dem mass spectrometry, and quantified by an isotope in-
ternal standard curve method [9].
In detail, HPLC-grade ethyl acetate was purchased from
Burdick & Jackson (Muskegon, MI). Ammonium acetate
(97.0% powder) was purchased from Junsei Chmical co.,
Ltd. (Tokyo, Japan). β-Glucuronidase (≥ 85,000 units/mL)
from Helix pomatia (Type H-2) and Bovine Serum Albu-
min (≥ 96.0% powder) were obtained from Sigma–Aldrich
(St. Louis, MO, USA). Urine sample was fortified with
50 μL of internal standard (200 ng/mL, 9 types mixer each
phthalate metabolites-13C12) spiking solution, 1mL of 2M
ammonium acetate buffer solution (1.54 g of ammonium
acetate / 10mL HPLC-grade water) and 20 μL of- β-Glu-
curonidase from Helix pomatia source. These samples
were incubated with overnight at 37 °C. And then, these
samples were extracted twice with 4mL of ethyl acetate.
These samples were gently shaken a few times and separ-
ate organic layer from non-polar fat layer by a centrifugal
at 4000 rpm for 15min. The chromatographic separation
was performed on a CAPCELL PAK C18 MG II column
(3.0mm× 150mm, 3 μm) from Shiseido co. Ltd. (Tokyo,
Japan). Target compound was performed with an Agilent
6430 Triple Quad liquid chromatograph mass spectrom-
eter equipped with Agilent 1200 series HPLC system (Agi-
lent Technologies Inc., Santa Clara, CA). These results
were analyzed by Eurofins Korea Analytic Service Co. Ltd.
Statistical analysis
Statistical analysis of the results was performed using
IBM SPSS Statistics ver. 25.0 (IBM Co., Armonk, NY,
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USA). All data were expressed as mean ± standard devi-
ation, and the paired t-test and ANOVA test were ap-
plied to compare the data. A P-value of < 0.05 was
considered significant.
Results
Clinical characteristics
Clinical characteristics of all participants are shown in
Table 1. In the CPP group, the CA and BA were 8.53 ±
0.65 years and 10.43 ± 0.68 years, respectively. The CA and
BA were 7.03 ± 1.37 and 6.51 ± 1.93 in the pre-pubertal con-
trol group and 11.18 ± 1.00 years and 11.39 ± 1.12 years in
the pubertal control group, respectively. The height SDS
was significantly different among these groups (P < 0.001).
BMI was not different between the groups. In the analysis
of sex hormone, the basal LH levels were 0.65 ± 0.56 mIU/
mL in the CPP group and 1.32 ± 1.43 mIU/mL in the pu-
bertal control group. The mean of LH peak of GnRH stimu-
lation in the CPP group was 14.3 ± 9.4 mIU/mL. In
addition, the kisspeptin levels were analyzed (data not
shown). The levels were 491.0 ± 198.7 pg/mL in the CPP
group and were 496.1 ± 314.4 and 2151.4 ± 1137.8 pg/mL in
the pre-pubertal and pubertal control groups, respectively.
The value for the pubertal control group was statistically
different from the values for the other two groups (P <
0.001).
Urinary concentration of phthalates and BPA
The urinary concentrations of the five phthalates and
BPA were obtained and creatinine-adjusted (Table 2).
The median values of MBzP, MECPP, MEHHP,
MEOHP, and MnBP were 3.1, 29.3, 18.0, 15.4, and
25.2 μg/g creatinine in the CPP group, 4.3, 53.7, 35.7,
29.1, and 66.0 μg/g creatinine in the pre-pubertal control
group, and 1.7, 28.7, 21.4, 12.1, and 33.3 μg/g creatinine
in the pubertal control group, respectively.
The urinary concentrations of all phthalate metabolites
were lower in the CPP group than in the pre-pubertal
control group (P = 0.026 for MBzP; P = 0.001 for
MEHHP; P < 0.001 for MECPP, MEOHP, and MnBP).
Furthermore, all phthalate metabolites had higher levels
in the pre-pubertal group than in the CPP group. Con-
versely, on comparing the CPP group and pubertal
control group, the urinary concentrations of the five
phthalate metabolites did not show significant difference
(P = 0.077 for MBzP, 0.733 for MECPP, 0.762 for
MEHHP, 0.405 for MEOHP, and 0.981 for MnBP). In
addition, urinary concentration of BPA showed same
pattern between groups, implying that the BPA level was
not significantly different between the CPP and pubertal
control groups. The median value of BPA was 0.63 μg/g
creatinine in the CPP group and 1.7 μg/g creatinine in
the pubertal control group (P = 0.092).
Discussion
The incidence of CPP is rising worldwide, particularly in
Korean children [2, 10, 11]. It is undetermined why the
incidence of CPP is increasing in Korean children. Fac-
tors contributing to the timing of puberty include gen-
etic and environmental factors [12]. Evidence for genetic
regulation of pubertal timing is supported by the obser-
vations that high correlation of the onset of puberty seen
within families, within racial/ethinic groups, and be-
tween monozygotic compared to dizygotic twins [13].
Secular trends in the timing of puberty over the past de-
cades indicate that environmental factors also influence
the timing of puberty. It is possible that environmental
factors, such as obesity, nutrition, dietary habits, physical
activity, and exposure to EDCs play an important role in
Table 1 Clinical and biochemical characteristics of CPP and controls
Variable CPP group (N = 47) Pre-pubertal Control group (N = 26) Pubertal Control group (N = 21) P value
CA (years) 8.53 ± 0.65 7.03 ± 1.37 11.18 ± 1.00 < 0.001
BA (years) 10.43 ± 0.68 6.51 ± 1.93 11.39 ± 1.12 < 0.001
Height (cm) 131.87 ± 5.84 113.41 ± 8.47 141.05 ± 9.34 0.002
Height SDS 0.23 ± 0.97 − 1.04 ± 0.66 −0.73 ± 0.86 < 0.001
BMI (kg/m2) 17.35 ± 2.67 15.02 ± 1.72 17.36 ± 2.49 0.06
Tanner stage 2.5 ± 0.50 (between stage 2–3) 1.0 ± 0.0 (stage 1) 3.0 ± 0.78 (stage 3) < 0.001
MPH (cm) 159.6 ± 3.99 158.2 ± 3.17 160.8 ± 4.23 0.066
Basal LH (mIU/mL) 0.65 ± 0.56 0.02 ± 0.35 1.32 ± 1.43 < 0.001
Basal FSH (mIU/mL) 3.71 ± 1.52 1.72 ± 0.62 4.92 ± 2.54 < 0.001
Basal E2 (pg/mL) below than 8 below than 8 17.3 ± 3.66
LH peak (mIU/mL) 14.3 ± 9.4
FSH peak (mIU/mL) 20.4 ± 8.8
Data are presented as mean ± standard deviation. CPP central precocious puberty, CA chronologic age, BA bone age, BMI body mass index, MPH mid-parental
height, LH luteinizing hormone, FSH follicle-stimulating hormone, E2 estradiol
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pubertal timing through directly or interacting the genes
regulating the puberty. Abrupt increase in the incidence
of CPP in Korean children suggests that environmental
factors, such as EDCs, are involved in the development
of CPP in Korea. Consequently, there have been consid-
erable concerns with the influence of EDCs, such as
phthalates and BPA, on precocious puberty because the
use of these chemicals is widespread, making the expos-
ure of people to these chemicals very easy and likely.
However, there have been no consistent reports suggest-
ing that phthalates and BPA promote the early onset of
puberty. Recent studies exploring the association be-
tween phthalate [14–18] or BPA [19–21] exposure and
pubertal timing are described in Table 3.
Some studies have reported associations between
phthalate exposure and early onset of puberty. Colon et
al. reported higher serum diethylhexyl phthalate levels in
41 thelarche patients than in 35 age-matched controls
[14]. They suggested that phthalates with weak estrogen
activity may disrupt the biologic system if they act at
critical periods of development. In addition, in a recent
study in Taiwan, all seven urinary phthalates were
Table 2 Urinary concentrations of phthalates and BPA in girls with CPP and control groups
CPP (N = 47) Pre-pubertal control (N = 26) P value CPP (N = 47) Pubertal control (N = 21) P value
MBzP (μg/g creatinine) 3.1 (1.8–4.9) 4.3 (3.3–11.1) 0.026 3.1 (1.8–4.9) 1.7 (0.64–4.6) 0.077
MECPP (μg/g creatinine) 29.3 (22.1–44.7) 53.7 (35.1–86.4) < 0.001 29.3 (22.1–44.7) 28.7 (22.7–45.6) 0.733
MEHHP (μg/g creatinine) 18.0 (14.6–28.5) 35.7 (23.0–54.3) 0.001 18.0 (14.6–28.5) 21.4 (13.5–29.4) 0.762
MEOHP (μg/g creatinine) 15.4 (12.1–25.0) 29.1 (18.7–35.9) < 0.001 15.4 (12.1–25.0) 12.1 (8.0–17.8) 0.405
MnBP (μg/g creatinine) 25.2 (10.9–151.0) 66.0 (39.4–106.1) < 0.001 25.15 (10.92–150.98) 33.3 (25.2–46.2) 0.981
Bisphenol A (μg/g creatinine) 0.63 (0.4–1.1) 2.0 (0.93–3.5) < 0.001 0.63 (0.4–1.1) 1.7 (1.1–3.3) 0.092
Data are presented as median and interquartile range. MBzP monobenzyl phthalate, MECPP mono-2-ethyl-5-carboxypentyl phthalate, MEHHP mono-2-ethyl-5-
hydroxyhexyl phthalate, MEOHP mono-2-ethyl-5-oxohexyl phthalate, MnBP mono-n-butyl phthalate
Table 3 Summary of recent studies on association between phthalates or BPA and puberty
Author (year), country Subjects Phthalates
or BPA
Results
Colon et al. [14] (2000)
Puerto Rico
41 thelarche patients,
35 controls
DBP, BBP,
DEP
MEHP
Elevated serum phthalates in premature thelarche
Chou et al. [15] (2009)
Taiwan
26 CPP,
30 premature thelarche
33 controls
MMP, MBuP
MBzP, MEHP
Urinary levels of MMP were higher in premature thelarche
(but not in CPP group)
None of the phthalates showed association with true
gonadotropin-dependent puberty
Lomenick et al. [16] (2010)
USA
28 CPP girls,
28 age-matched
controls
MBP, MBzP
MCPP,
MECPP
MEHHP,
MEHP
MEOHP,
MEP
MiBP
Phthalate exposure is not associated with precocious
puberty in female children.
Chen et al. [17] (2013)
Taiwan
73 CPP girls,
31 controls
MMP, MEP
MBP, MBzP
MEHP,
MEHHP
MEOHP
All seven urinary phthalate metabolite levels in the
CPP group were significantly higher (P < 0.05) than in
prepubescent controls.
Srilanchakon et al. [18]
(2007) Thailand
42 precocious puberty, 17 early puberty,
77 age-matched controls
MMP
MEP
Urinary MEP concentration was higher in girls with precocious
puberty than in controls
Durmaz et al. [19] (2014)
Turkey
28 CPP non-obese girls, 25 controls BPA Urinary BPA levels in CPP group were higher compared to
the control
Özgen et al. [20] (2016)
Turkey
28 CPP, 28 premature thelarche, 22
prepubertal controls
BPA Urinary BPA levels did not differentiate between groups
Chen et al. [21] (2018)
China
136 CPP, 136 age-, BMI-matched
controls
BPA BPA exposure was associated with increased incidence of CPP
CPP central precocious puberty, DBP dibutyl phthalate, BBP benzylbutyl phthalate, DEP diethyl phthalate, MEHP mono- (2-ethylhexyl) phthalate, MMP monomethyl
phthalate, MBuP monobutyl phthalate, MBzP monobenzyl phthalate, MBP mono-n-butyl phthalate, MCPP mono-3-carboxypropyl phthalate, MECPP mono (2-ethyl-5-
carboxypentyl) phthalate, MEHHP, mono (2-ethyl-5-hydroxyhexyl) phthalate, MEOHP mono (2-ethyl-5-oxohexyl) phthalate, MEP monoethyl phthalate, MiBP mono-
isobutyl phthalate, BPA bisphenol A
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significantly higher in the CPP group than in pre-puber-
tal controls [17]. Chen et al. also analyzed these groups
using estrogen receptor binding effect indices, and the
results were similar [17]. Meanwhile, a recent study in
the US showed no difference in nine urinary phthalates
between girls with CPP and pre-pubertal controls, sug-
gesting that phthalate exposure is not associated with
CPP [16]. They proposed some possibilities that phtha-
lates have no significant estrogen effect, or the corre-
sponding phthalate metabolites, which are formed
rapidly in vivo from their parent compound, have no sig-
nificant clinical estrogenic effect, although some phtha-
lates have weak estrogenic activity in vitro [22]. In
another study in Taiwan, monomethyl phthalate (MMP)
concentrations were higher in the premature thelarche
group (non-gonadotropin-dependent group, normal
variant) than in the control group but were not signifi-
cantly different from the concentrations in the CPP
group [15]. The level of any phthalate (including MMP)
was not significantly different between the CPP and con-
trol groups, and thus, the levels do not suggest an asso-
ciation with true gonadotropin-dependent puberty.
Additionally, in a study conducted in Shanghai, Xie et al.
found that phthalate exposure delayed the puberty in
men and that urinary phthalate concentrations were sig-
nificantly associated with constitutional delay of growth
and puberty [23]. In addition, the anti-androgenic effect
of phthalates on testosterone production has been
proven in animal experiments and in vitro [24, 25]. As-
sociation between BPA exposure and development of
CPP is also controversial. Some studies reported that
urinary levels of BPA in CPP group were significantly
higher compared to the controls [19, 21], while other
study did not show any difference between groups [20].
In our study, urinary concentrations of phthalate me-
tabolites and BPA were lower in girls with CPP than in
pre-pubertal controls and were similar to those of pu-
bertal controls. Our finding of comparable levels of
phthalates and BPA in CPP and pubertal control groups
suggests that phthalates and BPA are not associated with
the development of CPP. The lower urinary concentra-
tions of phthalates and BPA in girls with CPP than in
pre-pubertal controls in our study are not consistent
with previous studies. Our assumption is that lower
urinary concentrations of phthalates and BPA in girls
with CPP reflect the increased excretion of these metab-
olites rather than lesser exposure to them during the
progress of puberty. Urinary concentration of phthalates
and BPA can be influenced by the extent of exposure to
them and their excretion rate from the body. According
to the National Health and Nutrition Examination Sur-
vey (NHANES), the urine levels of all phthalates were
the highest in 6–11-year age group among all the groups
(6–11 years, 12–19 years, 20–59 years, and 60–80 years),
except for those of mono-ethyl phthalate (MEP) [26]. In
Korean Environmental Health Survey in Children and
Adolescents (KorEHS-C) comprising 351 students, a sig-
nificant decreasing trend of phthalate concentration with
increasing age was consistent with a US study [27]. In
our study, urinary concentrations of phthalate metabo-
lites and BPA were lower in pubertal normal controls
than in pre-pubertal controls. These findings suggest
that the excretion of urinary phthalates and BPA in-
creases with age and pubertal progression. However, it
should be determined whether the excretion of phtha-
lates and BPA from the body increases with age and pu-
bertal progression; further, the involved mechanism
should be elucidated through further investigations.
There are several possible reasons for the results of
the effect of phthalate exposure on puberty onset being
inconsistent among previous studies as well as in our
present study. First, the discrepancy in the results may
be related to the timing of phthalate exposure. It has
been hypothesized that puberty comprises a series of
network of processes which are regulated by numerous
genes and several environmental factors [28]. Therefore,
it is possible that humans are the most vulnerable to be-
ing affected by phthalate exposure only at a certain time
period (window period) or age range, or phthalate
exposure does not cause precocious puberty in any time.
Second, we do not know the normal reference range of
phthalates and BPA and the mechanisms that affect their
metabolism. In addition, many factors, such as age and
BMI may affect the level of phthalates and BPA. The
urine levels of phthalate metabolites reportedly decrease
with increasing age [26, 27]. BMI and waist circumfer-
ence can also affect the levels of phthalates, which are
highly variable in children by age and developmental sta-
tus and related in part to the timing of adiposity re-
bound [29]. Third, there is a possibility that technical
factors, such as analysis methods and the type of sample
container may lead to different results. Lastly, because
the half-life of any phthalate is very short, there is a
possibility that the urinary concentration of phthalates
has changed even with a lifestyle change of just a few
days. Recently, the Korean government has begun to
regulate the concentration of phthalates in children’s
products (including toys and all synthetic resins used
by children); the urinary concentration of phthalates
could change after this regulation by the government
comes into effect.
Our study has some limitations. The number of pa-
tients is insufficient to detect a significant difference in
phthalate levels between the groups. In addition, our
phthalate measurements were from a single urine sample
despite the short half-life of phthalates. Further, hetero-
geneity owing to regional diversity and differences in liv-
ing habits should be considered. Strengths of our study
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include that to our knowledge, this is the first study in-
volving the analysis of urinary phthalates between the
CPP and control groups in Korean girls.
Conclusions
We found no significant differences in urinary phthalates
and BPA between girls with CPP and pubertal controls.
Rather, phthalate metabolites and BPA were relatively
higher in the pre-pubertal group than in the CPP group.
Prospective, longitudinal, large-scale human studies are
needed.
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